Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

35 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Effects of alagebrium, an advanced glycation endproduct breaker, on exercise tolerance and cardiac function in patients with chronic heart failure.
Hartog JW, Willemsen S, van Veldhuisen DJ, Posma JL, van Wijk LM, Hummel YM, Hillege HL, Voors AA; BENEFICIAL investigators. Hartog JW, et al. Among authors: van wijk lm, van veldhuisen dj. Eur J Heart Fail. 2011 Aug;13(8):899-908. doi: 10.1093/eurjhf/hfr067. Epub 2011 Jun 13. Eur J Heart Fail. 2011. PMID: 21669961 Free article. Clinical Trial.
Effects of alagebrium, an advanced glycation end-product breaker, in patients with chronic heart failure: study design and baseline characteristics of the BENEFICIAL trial.
Willemsen S, Hartog JW, Hummel YM, Posma JL, van Wijk LM, van Veldhuisen DJ, Voors AA. Willemsen S, et al. Among authors: van wijk lm, van veldhuisen dj. Eur J Heart Fail. 2010 Mar;12(3):294-300. doi: 10.1093/eurjhf/hfp207. Epub 2010 Jan 25. Eur J Heart Fail. 2010. PMID: 20100811 Free article. Clinical Trial.
Abnormal pharmacokinetics of flecainide in a "nonresponder".
van Gelder IC, Crijns HJ, van Wijk LM, van Gilst WH, Lie KI. van Gelder IC, et al. Among authors: van gilst wh, van wijk lm. Clin Cardiol. 1988 May;11(5):353-5. doi: 10.1002/clc.4960110516. Clin Cardiol. 1988. PMID: 3133149 Free article.
35 results